# Autobahn Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/autobahn-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.autobahntx.com
- Total disclosed funding: $177M
- Latest round: Series C (Jun 20, 2024)
- Investors on record: 16

## About

Autobahn Therapeutics, Inc., based in San Diego, US, focuses on developing innovative regenerative medicines specifically targeting central nervous system (CNS) disorders through advanced brain-targeting chemistry platforms.Founded in 2017, Autobahn Therapeutics, Inc. is dedicated to creating transformative therapies for CNS disorders. The company has received funding through two notable deals, with the most recent being a Series C round on June 20, 2024, raising USD 100.825 mn led by Newpath Partners and supported by other prominent investors. Keith Lenden serves as the founder, while Kevin Finney is the current CEO.Autobahn Therapeutics specializes in the development of next-generation regenerative medicines focused on CNS disorders. Utilizing a brain-targeting chemistry platform, the company offers orally administered small molecule prodrugs designed for tailored central and peripheral distribution profiles. Key programs such as ABX-002, ABX-101, and ABX-003 are actively being developed for conditions like bipolar depression, primarily targeting healthcare providers in North America and Europe.The company generates revenue through strategic partnerships and clinical collaborations that aid in the development and commercialization of innovative therapies. Revenue streams include milestone payments from clinical trial progress, royalty agreements on product sales, and potential licensing fees from successful drug approvals. Autobahn Therapeutics focuses on flagship products like ABX-002, ensuring they are accessible to patients through appropriate pricing and reimbursement strategies.Following its Series C funding round in June 2024, where USD 100.825 mn was raised to support clinical trials for thyroid hormone beta receptor, Autobahn Therapeutics plans to advance its pipeline of CNS therapies. The funding will facilitate the two phases of clinical trials for its flagship products. Additionally, the company is exploring expansion into new geographic markets to enhance its reach and impact in CNS treatment.

## Funding rounds

- Series C, Jun 20, 2024, $101M — ARCH Venture Partners, Canaan Partners, Alexandria Venture Investments, Invus [DUP], Bristol-Myers Squibb Company, Pfizer Venture Investments, BVF Partners, Biogen, Section 32, GT Healthcare Capital Partners, Samsara BioCapital, Newpath Partners, Insight Equity Partners, Blue Owl, Monograph Capital
- Series B, Jun 9, 2020, $76M — ARCH Venture Partners, Alexandria Venture Investments, Invus [DUP], Bristol-Myers Squibb Company, Pfizer Venture Investments, BVF Partners, Cowen Investment Management, Section 32, Samsara BioCapital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B, Series C
- Invus [DUP] — Series B, Series C
- Bristol-Myers Squibb Company — Series B, Series C
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B, Series C
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B, Series C
- Cowen Investment Management — Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B, Series C
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B, Series C
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series C
- Biogen — Series C
- GT Healthcare Capital Partners (https://capitalatlas.ai/funds/gt-healthcare-capital-partners) — Series C
- Newpath Partners (https://capitalatlas.ai/funds/newpath-partners) — Series C
- Insight Equity Partners (https://capitalatlas.ai/funds/insight-equity-partners) — Series C
- Blue Owl (https://capitalatlas.ai/funds/blue-owl) — Series C
- Monograph Capital (https://capitalatlas.ai/funds/monograph-capital) — Series C